Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 5/20 | 0.39 |
| ▸ | KDR | P35968 | 3/20 | 0.39 |
| ▸ | AXL | P30530 | 2/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.36 |
| ▸ | CLK1 | P49759 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 4/20 | 0.36 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1136262 | 0.90 | MET (0.43) | METKDRAXLDYRK1AIDO1 | |
| SCHEMBL1136007 | 0.90 | ADORA3 (0.40) | METKDRAXLDYRK1ACLK1 | |
| SCHEMBL2493104 | 0.89 | MET (0.41) | METKDRAXLDYRK1AIDO1 | |
| SCHEMBL1136187 | 0.88 | ALDH1A1 (0.42) | METKDRAXLDYRK1AIDO1 | |
| SCHEMBL1136119 | 0.88 | MAOB (0.40) | METKDRAXLDYRK1AIDO1 | |
| SCHEMBL1136103 | 0.87 | MET (0.40) | METKDRAXLIDO1PRKAB2 | |
| SCHEMBL2584922 | 0.86 | PTGDR2 (0.50) | METKDRAXLPRKAB2PRKAG1 | |
| SCHEMBL1136059 | 0.85 | MET (0.40) | METKDRAXLIDO1 | |
| SCHEMBL1136320 | 0.85 | MET (0.44) | METKDRAXLIDO1PRKAB2 | |
| SCHEMBL1136136 | 0.84 | MOGAT2 (0.39) | METKDRAXLALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-10-20 | — | — | US | disclosed |
| US-9403773-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-06 | — | — | US | disclosed |
| US-9045464-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-06-02 | — | — | US | disclosed |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-05-01 | — | — | US | disclosed |
| US-8642619-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-12-13 | — | — | US | disclosed |
| US-8269011-B2 | Quinolone compound and pharmaceutical composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-09-18 | — | — | US | disclosed |
| EP-2152699-B1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | disclosed |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2152699-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-02-17 | — | — | EP | disclosed |
| WO-2008150029-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316168-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | MET 3987/4885KDR 3871/4885AXL 4492/4885 |
| US-20140121207-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | MET 3987/4885KDR 3871/4885AXL 4492/4885 |
| US-20160304461-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | MET 3987/4885KDR 3871/4885AXL 4492/4885 |
| US-20100130546-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | MET 3987/4885KDR 3871/4885AXL 4492/4885 |
| US-20150218101-A1 | QUINOLONE COMPOUND AND PHARMACEUTICAL COMPOSITION | PARK7, SNCA, LRRK2 | MET 3987/4885KDR 3871/4885AXL 4492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.